Balanced news tone
News Sentiment
ZNTL sentiment intelligence
Zentalis Pharmaceuticals Llc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
54 relevant articles
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
+9.4% over one week, +30.1% over four weeks, trend active, and below fair value.
Zentalis Pharmaceuticals (ZNTL) Edges Higher, Stabilizing Near Support After Recent Volatility - Entry Point Alerts
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
83/100 classification
One-week reaction
9.4%
Price confirming higher
Trend fit
Trend active
30.1% over four weeks
Fair value
-27.8%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
14
Neutral
37
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
dars.gov.et
Direct company coverage
Zentalis Pharmaceuticals (ZNTL) Edges Higher, Stabilizing Near Support After Recent Volatility - Entry Point Alerts
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jul 2026 19:44
- Source
- dars.gov.et
dars.gov.et
Direct company coverage
Zentalis Pharmaceuticals (ZNTL) Edges Higher, Stabilizing Near Support After Recent Volatility - Descending Triangle
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jul 2026 19:36
- Source
- dars.gov.et
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Quartr
Direct company coverage
Zentalis Pharmaceuticals (ZNTL) Study Update Summary
Zentalis Pharmaceuticals (ZNTL) provided a study update revealing that Azenosertib achieved objective response rates above 30% in heavily pretreated Cyclin E1+ platinum-resistant ovarian cancer patients, with particular efficacy in PARP inhibitor-resistant subgroups. The drug dem
- Tone
- Positive 73/100
- Event
- Macro sensitivity
- Published
- 08 Jul 2026 23:42
- Source
- Quartr
Quartr
Direct company coverage
Zentalis Pharmaceuticals (ZNTL) Jefferies Global Life Sciences Conference Summary
Zentalis Pharmaceuticals presented a summary of their Jefferies Global Life Sciences Conference, focusing on their WEE1 inhibitor, azenosertib, for Cyclin E1-positive platinum-resistant ovarian cancer. The drug shows over 30% objective response rates with durable responses, and t
- Tone
- Positive 80/100
- Event
- Macro sensitivity
- Published
- 08 Jul 2026 23:10
- Source
- Quartr
AD HOC NEWS
Direct company coverage
Zentalis Pharmaceuticals outlines its oncology focus as Nasdaq-listed biotech
Zentalis Pharmaceuticals is a clinical-stage oncology company listed on Nasdaq, specializing in developing targeted therapies for solid tumors. The company focuses on selective small-molecule inhibitors and combination strategies, aiming to improve outcomes for difficult-to-treat
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 08 Jul 2026 22:35
- Source
- AD HOC NEWS
Quartr
Direct company coverage
Zentalis Pharmaceuticals (ZNTL) Jefferies Global Healthcare Conference 2026 Summary
This article summarizes Zentalis Pharmaceuticals' presentation at the Jefferies Global Healthcare Conference 2026, focusing on their strategic plans for azenosertib. The drug targets platinum-resistant ovarian cancer, particularly in patients with cyclin E1 high protein expressio
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 08 Jul 2026 11:39
- Source
- Quartr
Ad-hoc-news.de
Direct company coverage
Zentalis Pharmaceuticals outlines oncology pipeline strategy as clinical programs advance
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 16:11
- Source
- Ad-hoc-news.de
Simply Wall Street
Direct company coverage
June 2026 Penny Stocks With Promising Potential
This article identifies three "penny stocks" with strong fundamentals and promising potential for June 2026, despite a flat market and high volatility. It highlights Zentalis Pharmaceuticals (ZNTL), Cytek Biosciences (CTKB), and Duluth Holdings (DLTH), detailing their financial h
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 11:09
- Source
- Simply Wall Street
www.marketscreener.com
Direct company coverage
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 3000 Value Benchmark
Zentalis Pharmaceuticals, Inc. (NasdaqGM: ZNTL), a clinical-stage biopharmaceutical company, has been added to the Russell 3000 Value Benchmark. The company focuses on developing small molecule therapeutics for cancer and is advancing azenosertib, a WEE1 inhibitor, for ovarian ca
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 29 Jun 2026 20:41
- Source
- www.marketscreener.com
marketscreener.com
Direct company coverage
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 3000 Index
Zentalis Pharmaceuticals, Inc. (NasdaqGM: ZNTL) has been added to the Russell 3000 Index. The clinical-stage biopharmaceutical company focuses on developing small molecule therapeutics for cancer, with its lead candidate, azenosertib, targeting WEE1 inhibition. This addition high
- Tone
- Positive 81/100
- Event
- Market update
- Published
- 29 Jun 2026 09:11
- Source
- marketscreener.com
TradingView
Direct company coverage
Price to book forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL
The article provides information regarding the "Price to book forward" for Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL). It appears to be a financial data page from TradingView, displaying basic company and market information for the stock, though specific financial figures are
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 11:39
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL
This article provides a brief mention of the enterprise value to revenue forward for Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL). It appears to be a stub or a data point from a financial platform, focusing on the company's financial metrics within the Biotechnology sector. The
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 22:11
- Source
- TradingView
TradingView
Direct company coverage
Zentalis Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ZNTL)
This article provides an overview of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) stock, covering current price, historical performance, and analyst forecasts. It details financial actuals and estimates, including market capitalization, earnings, and revenue, and answers common
- Tone
- Positive 61/100
- Event
- Earnings
- Published
- 25 Jun 2026 17:41
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL
This article briefly mentions the price to sales forward for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL). It appears to be a financial data snippet from a larger platform rather than an in-depth analysis. The content primarily focuses on navigation and platform features, with mi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 12:09
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL
This article provides financial information for Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), focusing on its forward price-to-earnings ratio. It is a brief data point from TradingView, offering a snapshot of the company's valuation metric without further analysis.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 23 Jun 2026 10:39
- Source
- TradingView
Stock Titan
Direct company coverage
Zentalis (ZNTL) director awarded 57,100 RSUs, boosting holdings to 307,521 shares
Zentalis Pharmaceuticals director David Michael Johnson was awarded 57,100 Restricted Stock Units (RSUs) as part of the company's Non-Employee Director Compensation Program. These RSUs, which vest by June 16, 2027, or the next annual stockholder meeting based on continued board s
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 03:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Zentalis (ZNTL) investors elect directors and ratify Ernst & Young at 2026 meeting
Zentalis Pharmaceuticals, Inc. (ZNTL) held its 2026 Annual Meeting of Stockholders on June 16, 2026, with a strong quorum of approximately 69.47% of outstanding common stock. Stockholders elected David Johnson and Jan Skvarka, Ph.D., as Class III directors until the 2029 Annual M
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 03:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Zentalis (ZNTL) director Enoch Kariuki granted 57,100 restricted stock units
Zentalis Pharmaceuticals director Enoch Kariuki has been granted 57,100 restricted stock units (RSUs) as an equity award, with no purchase price. These RSUs will vest on June 16, 2027, or the next annual stockholder meeting, contingent on his continued service on the board. Follo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 20:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Zentalis Pharmaceuticals (ZNTL) director awarded 57,100 RSUs
Zentalis Pharmaceuticals director Scott Dunseth Myers was granted 57,100 restricted stock units (RSUs) at no cash cost, increasing his direct holdings to 395,895 shares. These RSUs will vest on the earlier of June 16, 2027, or the next annual stockholder meeting, contingent on hi
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 18 Jun 2026 19:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
Zentalis Pharmaceuticals (ZNTL) director granted 57,100 restricted stock units
Zentalis Pharmaceuticals director Luke Nathaniel Walker was granted 57,100 restricted stock units (RSUs) as part of a compensation package. These RSUs increase his direct holdings to 201,384 shares and will vest on the earlier of June 16, 2027, or the next annual stockholders mee
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 19:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
RSU grant boosts Zentalis (ZNTL) director Jan Skvarka's holdings
Zentalis Pharmaceuticals director Jan Skvarka received 57,100 restricted stock units (RSUs) as equity compensation, which are granted at no cash cost and will vest on June 16, 2027, or the next annual stockholder meeting, contingent on continued board service. This grant increase
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 18 Jun 2026 19:40
- Source
- Stock Titan
TradingKey
Direct company coverage
Zentalis Pharmaceuticals Inc (ZNTL) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Zentalis Pharmaceuticals Inc (ZNTL)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page primarily serves as a financial data p
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 17 Jun 2026 05:11
- Source
- TradingKey
TradingKey
Direct company coverage
Zentalis Pharmaceuticals Inc (ZNTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Zentalis Pharmaceuticals Inc (ZNTL), noting that relevant data for business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly shows a placeholder for revenue by region, indicati
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 05:11
- Source
- TradingKey
TradingView
Direct company coverage
Number of shareholders of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL
The article provides information about Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), focusing on investor-related data such as the number of shareholders. It appears to be a financial data page from TradingView, offering an overview of the company's stock, financials, and other
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 03:39
- Source
- TradingView
Simply Wall Street
Direct company coverage
Zentalis Pharmaceuticals Insider Sellers Vindicated After 10% Drop
Insiders at Zentalis Pharmaceuticals (NASDAQ: ZNTL) appear vindicated after the company's stock dropped 10%, leading to a US$28m market cap plunge. Over the last year, insiders, particularly the SVP of Finance Vincent Vultaggio, sold US$117k worth of stock at an average price of
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 09 Jun 2026 11:09
- Source
- Simply Wall Street
Intellectia AI
Direct company coverage
ZNTL Should I Buy
An analysis of Zentalis Pharmaceuticals Inc (ZNTL) stock suggests it is not an immediate buy for long-term investors, recommending a "Hold" position. The stock shows technical weakness despite bullish options sentiment and a recent positive analyst rating from Guggenheim. Concern
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 05 Jun 2026 22:10
- Source
- Intellectia AI
GlobeNewswire
Direct company coverage
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals announced that its Compensation Committee granted non-qualified stock options for 191,000 shares to two new employees. These grants were made under the 2022 Employment Inducement Incentive Award Plan, per Nasdaq Listing Rule 5635(c)(4), to attract new tal
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 08:40
- Source
- GlobeNewswire
Moomoo
Direct company coverage
Press Release: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals announced inducement grants to two new employees in accordance with Nasdaq Listing Rule 5635(c)(4). These grants, consisting of non-qualified stock options to purchase 30,000 shares of common stock, were approved by the independent compensation committee
- Tone
- Positive 62/100
- Event
- Market update
- Published
- 01 Jun 2026 20:40
- Source
- Moomoo
Stock Titan
Direct company coverage
Zentalis (ZNTL) director Shannon Campbell receives 114,200-share RSU award
Zentalis Pharmaceuticals director Shannon Campbell was granted 114,200 restricted stock units (RSUs) as part of the company's Non-Employee Director Compensation Program. These RSUs, which were issued at no purchase price, will vest in three equal installments on the first, second
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 17:39
- Source
- Stock Titan